Hanall Biopharma launches Pangro Solution: KRW 2.2 trillion values Hanall Biopharma stock

Published on 10/20/2026 at 01:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanall Biopharma launched a 200 mL topical treatment on October 8, 2026. Hanall Biopharma stock has a KRW 2.2 trillion market value.

Pipeline expansion

Hanall Biopharma launched a 200 mL Pangro Solution 5% product on October 8, 2026.
Second-quarter revenue rose 8.8 percent to KRW 44.3 billion, while operating profit reached KRW 5.6 billion.
Hanall Biopharma had a KRW 2.2 trillion market value as of October 19, 2026.

Hanall Biopharma, KR7009420001, Illustration mit AI erstellt.

Hanall Biopharma launched Pangro Solution 5%, a 200 mL topical minoxidil treatment, on October 8, 2026. The product expands the companys hair loss portfolio from oral medicines into a directly applied format, according to Asiae.

Hair loss lineup gains a topical format

Pangro Solution 5% contains minoxidil and is sold as an over-the-counter medicine for male-pattern hair loss. Hanall Biopharma already marketed Hairgro tablets, Adamo tablets, Adamo soft capsules and Pangro capsules, giving the new product a place alongside four established oral or adjunctive formulations.

The company said it had built a dedicated hair loss production line at its Daejeon plant in 2022. The line uses automated production and a closed manufacturing process, linking the October 8 launch to an operating platform developed over four years.

Three milestones shape the pipeline

On June 30, 2026, Hanall Biopharma reported second-quarter revenue of KRW 44.3 billion, up 8.8 percent from a year earlier, and operating profit of KRW 5.6 billion, according to ATS View. On September 24, 2026, the company halted development of imerofrubat for cutaneous lupus after the trial failed to show statistical significance, while five other indications continued, Chosun Biz reported.

What does the pipeline mean for earnings?

The second-quarter income statement also included a KRW 19.2 billion net loss, so the operating profit did not translate into bottom-line earnings. The contrast leaves product sales and licensing milestones as separate earnings drivers: Pangro can support the commercial base, while the partnered autoimmune pipeline carries larger development and regulatory uncertainty.

Next filing date is November 16, 2026

ATS View lists November 16, 2026 as the filing deadline for the report covering the September 2026 period. That date is the next concrete reporting milestone currently identified for the company.

Market value and operating context

Hanall Biopharma had a market capitalization of KRW 2.2 trillion as of October 19, 2026. Its 52-week range was KRW 32,600 to KRW 73,000 on the same date, putting the commercial launch beside a valuation shaped by both recurring products and clinical development outcomes.